MAPT and Alzheimer disease: Given that P-tau is a hallmark of AD, associated with neurofibrillary tangles and characteristic disease features, the ability of GLS to influence tau phosphorylation underscores its potential as a therapeutic agent for modulating tau pathology in AD.